AxoGen Inc. (AXGN)
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Company Description
AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves.
The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.
Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive Soft Tissue Membrane, a processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues in the surgical bed.
In addition, the company offers AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin.
It provides its products to hospitals, surgery centers, and military hospitals plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons in the United States, Canada, Germany, the United Kingdom and other European countries, South Korea, and internationally.
AxoGen, Inc. is headquartered in Alachua, Florida.
Country | United States |
IPO Date | Dec 17, 1986 |
Industry | Medical - Devices |
Sector | Healthcare |
Employees | 426 |
CEO | Nir Naor C.F.A., CPA, L.L.M., M.B.A. |
Contact Details
Address: 13631 Progress Boulevard Alachua, Florida United States | |
Website | https://www.axogeninc.com |
Stock Details
Ticker Symbol | AXGN |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0000805928 |
CUSIP Number | 05463X106 |
ISIN Number | US05463X1063 |
Employer ID | 41-1301878 |
SIC Code | 3845 |
Key Executives
Name | Position |
---|---|
Jens Schroeder Kemp | Chief Marketing Officer |
Nir Naor C.F.A., CPA, L.L.M., M.B.A. | Chief Financial Officer |
Craig A. Swandal | Vice President of Operations |
Doris Quackenbush | Vice President of Sales |
Dr. Ivica Ducic M.D., Ph.D. | Chief Medical Officer |
Erick DeVinney | Chief Innovation Officer |
Harold D. Tamayo | Vice President of Finance & Investor Relations |
Karen Zaderej | Advisor |
Marc A. Began | Executive Vice President, General Counsel & Chief Compliance Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Jan 10, 2025 | 8-K | Current Report |
Jan 08, 2025 | SCHEDULE 13G/A | [Amend] Filing |
Jan 06, 2025 | 5 | Filing |
Jan 06, 2025 | 4 | Filing |
Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
Nov 07, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
Nov 07, 2024 | 10-Q | Quarterly Report |
Nov 07, 2024 | 8-K | Current Report |
Sep 17, 2024 | 4 | Filing |
Sep 13, 2024 | 4 | Filing |